Assay Service for assessing ADME properties and in vivo PK properties with the selected vendor. ENAMINE US INC
- Response deadline
- Sep 19, 2026 Due in 8 days
- Date posted
- Sep 10, 2026
- Source
- Open notice
Description
The Section on Medicinal Chemistry (SMC) develops new molecular entities with implications in improving health and treatment for various metabolic and alcohol associated diseases. To assess the translational potential of novel molecular entities, which would allow us to make decisions to proceed the compounds for further development we utilize multiple derisking assays. These assays comprise of both cell-based (in vitro) testing and then eventually in mice to assess pharmacokinetic parameters to see if the drug is orally available. Request to procure Chemical Reagent (Assay) Development & Laboratory Testing Service SMC to produce grouped ADME assays and perform a Pharmacokinetic study in C57BL6 mice. By including the Caco-2 Permeability Assay in our ADME evaluation it'll accurately predict the oral absorption potential of our compounds. This well-established in vitro model closely mimics the human intestinal epithelium, providing critical insights into a compound’s passive diffusion, active transport, and efflux processes, such as those mediated by P-glycoprotein (P-gp). The data generated from this assay are vital for informing structure-activity relationship (SAR) optimization, improving compound permeability, and reducing transporter-related liabilities that could hinder bioavailability
Classifications
Documents (1)
- SOW ENAMINE US INC.pdf.pdf254 KBNot yet available
Contacts
Similar contracts
- Assay Service for assessing ADME properties and in vivo PK properties with the selected vendorMarylandDue Sep 3, 2026
- Ultracold Freezers for long-term sample and reagent storageMDDue Aug 5, 2026
- Chemical Dosing Skid Pump SystemTXDue Aug 10, 2026
- Chemical Dosing Skid Pump SystemTXDue Aug 2, 2026
- Explosives and Explosive ProductsALDue Jul 10, 2026
- ExplosivesALDue Jun 24, 2026